Extension study for a refillable eye implant plus ranibizumab
Part of Eyes & vision clinical trials.
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously completed a specific earlier Roche eye study (or were/weren’t eligible in another specific study at a certain time)
- You can attend all scheduled visits and eye scans/procedures during the trial
- If you can become pregnant, you must use birth control (or stay abstinent) during the study and for the required time after last treatment
- You must have the right wet macular degeneration history and show benefit from prior injections (for sub-study 1)
- You must not be pregnant or breastfeeding, and you must avoid becoming pregnant for a set time after injections or implant refills
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
This Phase 3 study tests whether a small eye implant that delivers medicine on a schedule (the port delivery system) with ranibizumab works better and safely in people with wet age-related macular degeneration. It’s designed for patients who have already been treated recently with anti-VEGF injections and need continued control.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.